智能胰岛素输送系统的有希望的战略:对葡萄糖敏感的微针
Xiang Chen1, Xiaojie Dou2, Wei Qiu3
1Yangtze Delta Region Institute (Huzhou), University of Electronic Science and Technology of China, Huzhou, 313000, PR China.
European journal of medicinal chemistry
|August 31, 2024
概括
新的对葡萄糖敏感的微针贴片 (GSMP) 提供精确的胰岛素输送. 全合一的GSMP显示出比组装型更好的血糖控制相关性,促进了糖尿病治疗.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病管理正在通过智能治疗干预措施取得进展.
- 对葡萄糖敏感的微针贴片 (GSMP) 提供基于葡萄糖水平的自动化,通过皮肤输送胰岛素.
研究的目的:
- 将GSMP分为集成,全合一和核心外结构.
- 分析不同GSMP结构的机制,性能和临床翻译挑战.
- 探索葡萄糖敏感性能与正常血糖维持时间 (NGT) 之间的相关性.
主要方法:
- 为GSMPs提出了一个新的分类系统.
- 分析了每个GSMP类型的工作机制和性能特征.
- 研究了体外释放性能与体内血糖控制之间的关系.
主要成果:
- 全集GSMP在体外葡萄糖敏感释放和NGT之间呈现出正相关性.
- 组装的GSMP的表现取决于矩阵材料和交叉链接,与NGT没有直接相关.
- 确定了GSMP临床翻译的关键挑战和未来趋势.
结论:
- 拟议的分类有助于理解GSMP机制和性能.
- 全合一的GSMP显示出由于直接的性能-NGT相关性,有望改善糖尿病管理.
- 需要进一步的研究和开发,以克服高级GSMPs的临床翻译障碍.
相关概念视频
Insulin Formulations: Types and Delivery
177
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
177
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Insulin: Biosynthesis, Chemistry, and Preparation
365
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
365
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Insulin: Dosing Regimen and Adverse Effects
160
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
160


